# Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

> **NCT04504396** · PHASE3 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 620 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** GLP-1 receptor agonist
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04504396
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-23
- **Primary completion:** 2022-09-15
- **Final completion:** 2023-05-26
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504396, "Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04504396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*